A clinical-stage biotech firm developing next-generation therapies to treat severe acute respiratory failure, currently funded by significant cash reserves and equity issuances.
Early investors may benefit from high optionality value if any clinical candidates successfully reach market approval in the respiratory care sector. The company's substantial cash reserves and ability to raise capital through equity issuances provide a runway for critical milestone achievements. Potential strategic partnerships with larger pharmaceutical companies could significantly enhance valuation upon positive clinical data readouts.
The absence of revenue and persistent annual losses make the business model highly speculative and vulnerable to funding droughts. Any failure in clinical trials would likely result in significant stock price depreciation given the binary nature of biotech asset development. Dilutive equity issuances required to fund operations could further erode shareholder value in the absence of commercial product sales.
Jasper Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for severe acute respiratory failure. The company primarily serves the global medical market with its proprietary drug candidates targeting critical care conditions. Key products are currently in preclinical or early clinical development stages as the firm advances its research pipeline.
Recent financial performance shows continued heavy investment in research and development with operating expenses totaling over $76 million. The company reported a net loss of $71.3 million, reflecting its clinical-stage status and lack of commercial revenue generation. Despite the cash burn, the firm maintained a healthy cash position of approximately $72 million, enabling continued pursuit of its drug development goals.
The severe acute respiratory failure market represents a growing therapeutic area with increasing demand for novel treatments following global health crises. Biopharmaceutical companies in this space face intense competition from established players and must navigate lengthy regulatory approval processes. Success requires substantial capital investment over extended periods before any potential commercial returns materialize.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $51.2M | $68.9M | $76.2M |
| Operating Income | $-51.2M | $-68.9M | $-76.2M |
| R&D | $34.6M | $51.8M | $55.8M |
| G&A | $16.6M | $17.1M | $20.4M |
| Stock-Based Comp | $4.1M | $5.2M | $6.6M |
| D&A | $975.0K | $1.1M | $1.4M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | — | $5.2M | $5.1M |
| Pre-Tax Income | $-51.2M | $-68.9M | $-76.2M |
| Income Tax | $-88.9M | $-4.4M | $2.0K |
| Continuing Ops | $37.7M | $-64.5M | $-76.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $37.7M | $-64.5M | $-71.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $37.7M | $-64.5M | $-71.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $41.7M | $88.9M | $75.8M |
| Cash & Equivalents | $38.2M | $86.9M | $71.6M |
| Prepaid Expenses | $2.8M | $2.1M | $4.2M |
| Other Current Assets | $663.0K | $0 | $0 |
| Long-Term Assets | $6.6M | $6.0M | $4.1M |
| PP&E (Net) | $3.6M | $2.7M | $1.9M |
| Operating Leases | $1.9M | $1.5M | $976.0K |
| Other LT Assets | $1.2M | $1.8M | $1.2M |
| Total Assets | $48.4M | $94.9M | $79.9M |
| Current Liabilities | $7.1M | $12.4M | $15.2M |
| Accounts Payable | $1.8M | $4.1M | $4.0M |
| Current Leases | $865.0K | $972.0K | $1.1M |
| Other Current Liab | $4.4M | $7.3M | $10.1M |
| Long-Term Liabilities | $5.3M | $4.1M | $3.0M |
| LT Operating Leases | $2.8M | $1.8M | $724.0K |
| Other LT Liab | $2.5M | $2.3M | $2.3M |
| Total Liabilities | $12.4M | $16.5M | $18.2M |
| Shareholders' Equity | $36.0M | $78.4M | $61.7M |
| Paid-In Capital | $141.1M | $248.0M | $302.5M |
| Retained Earnings | $-105.1M | $-169.6M | $-240.9M |
| Total L&E | $48.4M | $94.9M | $79.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $37.7M | $-64.5M | $-71.3M |
| Non-Cash Adjustments | $-85.2M | $9.0M | $5.3M |
| Working Capital Changes | $1.6M | $3.4M | $3.4M |
| Cash from Operations | $-45.9M | $-52.1M | $-62.6M |
| Cash from Investing | $-576.0K | $-267.0K | $-532.0K |
| Cash from Financing | $55.0K | $101.0M | $47.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-46.4M | $48.6M | $-15.2M |
| Beginning Cash | $85.0M | $38.7M | $87.3M |
| Ending Cash | $38.7M | $87.3M | $72.1M |
The company operates primarily through a single business segment dedicated to drug discovery and development for respiratory failure treatments. Financials indicate heavy allocation to research and development expenses with no current product revenue streams from commercial sales. All operational activities are centered on advancing clinical candidates rather than selling established pharmaceutical products.
Significant cash burn from operations coupled with substantial net losses threatens long-term solvency if financing is not secured. Complete absence of commercial revenue creates high dependence on successful clinical trial outcomes and future capital raising events. High volatility in biotech valuations exposes the stock to market sentiment shifts unrelated to intrinsic business fundamentals.
The company possesses a proprietary pipeline of novel therapeutics targeting unmet needs in severe acute respiratory failure markets. Strong balance sheet liquidity provides flexibility for R&D execution and potential strategic partnerships without immediate revenue pressure. Specialized scientific expertise in respiratory medicine offers a distinct moat against generic competitors in this niche therapeutic area.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.